A very recent study showed that stage II and III dMMR rectal tumors were very sensitive to dostarlimab, another anti-PD-1 mAb, with a complete clinical response for all patients included (n = 12) [40]. This evidence concerns the gene PDCD1 and rectal neoplasm.